title: Sorafenib for patients with differentiated thyroid cancer.
authors.affiliation: Departments of Medical Oncology, Cochin Hospital, Paris, 75006, France; Paris Descartes University, Paris, France. Electronic address: olivier.huillard@cch.aphp.fr.
authors.forename: Olivier
authors.initials: O
authors.lastname: Huillard
authors.affiliation: Pharmacokinetics and Pharmacochemistry Unit, Cochin Hospital, Paris, 75006, France; Paris Descartes University, Paris, France.
authors.forename: Benoit
authors.initials: B
authors.lastname: Blanchet
authors.affiliation: Departments of Medical Oncology, Cochin Hospital, Paris, 75006, France; Paris Descartes University, Paris, France.
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Durand
authors.affiliation: Departments of Medical Oncology, Cochin Hospital, Paris, 75006, France; Paris Descartes University, Paris, France.
authors.forename: François
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D013964:Thyroid Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide